Levodopa in postencephalitic parkinsonism.
D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced; D009069:Movement Disorders / Q000139:chemically induced; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy*; D012131:Respiratory Insufficiency / Q000139:chemically induced; D013927:Thrombosis / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine